{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 449870959
| IUPAC_name = 6-fluoro-5-methyl-2-[(5-methyl-1''H''-imidazol-4-yl)methyl]-2,3,4,5-tetrahydro-1''H''-pyrido[4,3-''b'']indol-1-one
| image = Lurosetron.png

<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration =  

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number        = 128486-54-4
| CAS_supplemental = <br>{{CAS|143486-90-2}} (mesylate)
| ATC_prefix = none
| ATC_suffix =  
| ATC_supplemental =  
| PubChem = 172999
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = G694G740ZP
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D04821
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID      = 151068

<!--Chemical data-->
| chemical_formula =  
| C=17 | H=17 | F=1 | N=4 | O=1 
| molecular_weight = 312.341 g/mol
| smiles = CC1=C(N=CN1)CN2CCC3=C(C2=O)C4=C(N3C)C(=CC=C4)F
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI          = 1S/C17H17FN4O/c1-10-13(20-9-19-10)8-22-7-6-14-15(17(22)23)11-4-3-5-12(18)16(11)21(14)2/h3-5,9H,6-8H2,1-2H3,(H,19,20)
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey       = NUMKWGDDRWJQMY-UHFFFAOYSA-N
}}

'''Lurosetron''' ([[International Nonproprietary Name|INN]]) is a [[serotonin]] [[5-HT3 antagonist|5-HT<sub>3</sub> receptor antagonist]].<ref>Prakash SP, Cable KM, Correa ID, Fellows L, Montgomery S, Newman JJ, Waterhouse L, Wells GN, Sutherland DR. Synthesis of isotopically labelled pyridoindolone 5-HT3 receptor antagonists. ''Journal of Labelled Compounds and Radiopharmaceuticals''. 1995; 36(10):993-1007.</ref>

==Synthesis==
[[File:Lurosetron synthesis.svg|thumb|center|700px|Lurosetron synthesis: {{Cite patent|EP|0353983}}]]

==References==
<references/>

[[Category:5-HT3 antagonists]]
[[Category:Imidazoles]]


{{gastrointestinal-drug-stub}}